FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134499059> ?p ?o ?g. }

• W3134499059 endingPage "1447" @default.
• W3134499059 startingPage "1438" @default.
• W3134499059 abstract "Purpose This study characterizes the association of risk factors including race, ethnicity, and insurance status with presenting visual acuity (VA) and diabetic retinopathy (DR) severity in patients initiating treatment with anti–vascular endothelial growth factor (VEGF) therapy for diabetic macular edema (DME). Design Retrospective, cross-sectional study. Participants The Academy Intelligent Research in Sight (IRIS) Registry database was queried for patients who initiated anti-VEGF injection treatment for DME between 2012 and 2020 (n = 203 707). Methods Multivariate regression analyses were conducted to understand how race, ethnicity, insurance status, and geographic location were associated with baseline features. Main Outcome Measures Visual acuity and DR severity. Results Patients on Medicare and private insurance presented with higher baseline VA compared with patients on Medicaid (median of 2.31 and 4.17 greater Early Treatment Diabetic Retinopathy Scale [ETDRS] letters, respectively P < 0.01). White and non-Hispanic patients presented with better VA compared with their counterparts (median of 0.68 and 2.53 greater ETDRS letters, respectively; P < 0.01). Black and Hispanic patients presented with a worse baseline DR severity compared with White and non-Hispanic patients (odds ratio, 1.23 and 1.71, respectively; P < 0.01). Conclusions There are ethnic and insurance-based disparities in VA and disease severity upon initiation of anti-VEGF therapy for DME treatment. Public health initiatives could improve timely initiation of treatment. This study characterizes the association of risk factors including race, ethnicity, and insurance status with presenting visual acuity (VA) and diabetic retinopathy (DR) severity in patients initiating treatment with anti–vascular endothelial growth factor (VEGF) therapy for diabetic macular edema (DME). Retrospective, cross-sectional study. The Academy Intelligent Research in Sight (IRIS) Registry database was queried for patients who initiated anti-VEGF injection treatment for DME between 2012 and 2020 (n = 203 707). Multivariate regression analyses were conducted to understand how race, ethnicity, insurance status, and geographic location were associated with baseline features. Visual acuity and DR severity. Patients on Medicare and private insurance presented with higher baseline VA compared with patients on Medicaid (median of 2.31 and 4.17 greater Early Treatment Diabetic Retinopathy Scale [ETDRS] letters, respectively P < 0.01). White and non-Hispanic patients presented with better VA compared with their counterparts (median of 0.68 and 2.53 greater ETDRS letters, respectively; P < 0.01). Black and Hispanic patients presented with a worse baseline DR severity compared with White and non-Hispanic patients (odds ratio, 1.23 and 1.71, respectively; P < 0.01). There are ethnic and insurance-based disparities in VA and disease severity upon initiation of anti-VEGF therapy for DME treatment. Public health initiatives could improve timely initiation of treatment." @default.
• W3134499059 created "2021-03-15" @default.
• W3134499059 creator A5001385468 @default.
• W3134499059 creator A5050802337 @default.
• W3134499059 creator A5069234226 @default.
• W3134499059 creator A5079973052 @default.
• W3134499059 creator A5085213833 @default.
• W3134499059 creator A5086184962 @default.
• W3134499059 date "2021-10-01" @default.
• W3134499059 modified "2023-10-16" @default.
• W3134499059 title "Racial, Ethnic, and Insurance-Based Disparities Upon Initiation of Anti–Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in the US" @default.
• W3134499059 cites W1979162551 @default.
• W3134499059 cites W1992103610 @default.
• W3134499059 cites W1994409536 @default.
• W3134499059 cites W2002928248 @default.
• W3134499059 cites W2010456451 @default.
• W3134499059 cites W2016795705 @default.
• W3134499059 cites W2020482183 @default.
• W3134499059 cites W2023642003 @default.
• W3134499059 cites W2040687250 @default.
• W3134499059 cites W2051202229 @default.
• W3134499059 cites W2054306220 @default.
• W3134499059 cites W2075206985 @default.
• W3134499059 cites W2078206563 @default.
• W3134499059 cites W2106874613 @default.
• W3134499059 cites W2133071935 @default.
• W3134499059 cites W2139243023 @default.
• W3134499059 cites W2141864382 @default.
• W3134499059 cites W2148477686 @default.
• W3134499059 cites W2150923327 @default.
• W3134499059 cites W2150942767 @default.
• W3134499059 cites W2325781243 @default.
• W3134499059 cites W2342360716 @default.
• W3134499059 cites W2553648184 @default.
• W3134499059 cites W2590312224 @default.
• W3134499059 cites W2782932304 @default.
• W3134499059 cites W2888464051 @default.
• W3134499059 cites W2899990204 @default.
• W3134499059 cites W2924592455 @default.
• W3134499059 cites W2938554156 @default.
• W3134499059 cites W4211031298 @default.
• W3134499059 doi "https://doi.org/10.1016/j.ophtha.2021.03.010" @default.
• W3134499059 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33716048" @default.
• W3134499059 hasPublicationYear "2021" @default.
• W3134499059 type Work @default.
• W3134499059 sameAs 3134499059 @default.
• W3134499059 citedByCount "17" @default.
• W3134499059 countsByYear W31344990592021 @default.
• W3134499059 countsByYear W31344990592022 @default.
• W3134499059 countsByYear W31344990592023 @default.
• W3134499059 crossrefType "journal-article" @default.
• W3134499059 hasAuthorship W3134499059A5001385468 @default.
• W3134499059 hasAuthorship W3134499059A5050802337 @default.
• W3134499059 hasAuthorship W3134499059A5069234226 @default.
• W3134499059 hasAuthorship W3134499059A5079973052 @default.
• W3134499059 hasAuthorship W3134499059A5085213833 @default.
• W3134499059 hasAuthorship W3134499059A5086184962 @default.
• W3134499059 hasConcept C118487528 @default.
• W3134499059 hasConcept C126322002 @default.
• W3134499059 hasConcept C134018914 @default.
• W3134499059 hasConcept C137403100 @default.
• W3134499059 hasConcept C144024400 @default.
• W3134499059 hasConcept C156957248 @default.
• W3134499059 hasConcept C167135981 @default.
• W3134499059 hasConcept C19165224 @default.
• W3134499059 hasConcept C2778257484 @default.
• W3134499059 hasConcept C2779829184 @default.
• W3134499059 hasConcept C555293320 @default.
• W3134499059 hasConcept C71924100 @default.
• W3134499059 hasConceptScore W3134499059C118487528 @default.
• W3134499059 hasConceptScore W3134499059C126322002 @default.
• W3134499059 hasConceptScore W3134499059C134018914 @default.
• W3134499059 hasConceptScore W3134499059C137403100 @default.
• W3134499059 hasConceptScore W3134499059C144024400 @default.
• W3134499059 hasConceptScore W3134499059C156957248 @default.
• W3134499059 hasConceptScore W3134499059C167135981 @default.
• W3134499059 hasConceptScore W3134499059C19165224 @default.
• W3134499059 hasConceptScore W3134499059C2778257484 @default.
• W3134499059 hasConceptScore W3134499059C2779829184 @default.
• W3134499059 hasConceptScore W3134499059C555293320 @default.
• W3134499059 hasConceptScore W3134499059C71924100 @default.
• W3134499059 hasFunder F4320306811 @default.
• W3134499059 hasIssue "10" @default.
• W3134499059 hasLocation W31344990591 @default.
• W3134499059 hasOpenAccess W3134499059 @default.
• W3134499059 hasPrimaryLocation W31344990591 @default.
• W3134499059 hasRelatedWork W1980355846 @default.
• W3134499059 hasRelatedWork W2007982614 @default.
• W3134499059 hasRelatedWork W2064970495 @default.
• W3134499059 hasRelatedWork W2113257626 @default.
• W3134499059 hasRelatedWork W2348506863 @default.
• W3134499059 hasRelatedWork W2371917728 @default.
• W3134499059 hasRelatedWork W2381483116 @default.
• W3134499059 hasRelatedWork W2389579140 @default.
• W3134499059 hasRelatedWork W2808021644 @default.
• W3134499059 hasRelatedWork W2512568326 @default.
• W3134499059 hasVolume "128" @default.
• W3134499059 isParatext "false" @default.

• next